Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of ...

Reproductive health researchers found a rarely discussed "pathway" between the effect and its unexpected cause.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...